Navigation Links
Five-Year Follow-Up Data on CERAMENT™|BONE VOID FILLER Demonstrates Long-Term Safety and Long-Lasting Bone Mineral Density Improvement in Osteoporotic Patients
Date:10/28/2013

Lund, Sweden (PRWEB) October 28, 2013

BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a five-year follow-up study on patients treated with CERAMENT™|BONE VOID FILLER, as presented at the Combined Orthopaedic Research Society (CORS) meeting in Venice, Italy. The study demonstrates long-term safety and long-lasting bone mineral density improvement, following bone remodeling after treatment with CERAMENT™|BONE VOID FILLER in osteoporotic patients.

“The study results confirm what we know to be true about CERAMENT™, its osteoconductive characteristics create a stable framework to support new bone growth, making it a safe and effective solution to filling voids such as correction osteotomies following malunited distal radius fractures,” said Professor Magnus Tägil, lead investigator in the study. “More importantly, the full bone remodeling seen within a year after CERAMENT™ treatment seems to be a long-lasting solution because the normalized bone mineral density persists at least for five years, as demonstrated in the present study.”

The aim of the study was to evaluate the long-term performance of CERAMENT™|BONE VOID FILLER in correction osteotomy following malunited distal radius fractures, a common complication after this fracture. Most often, an iliac crest bone graft is used to fill the void, however, this method is associated with a high incidence rate of donor site morbidity.

“We believe CERAMENT™|BONE VOID FILLER offers significant advantages over current treatment methods and we are pleased to see the positive outcomes demonstrated in this study,” said Lloyd Diamond, CEO of BONESUPPORT. “Studies such as this help improve and advance medical care and help health care decision makers direct resources to the strategies and treatments that work best.”

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G is the first CE-marked injectable antibiotic eluting ceramic bone graft substitute. CERAMENT™|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries. CERAMENT™|G is not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 6,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT, please visit http://www.bonesupport.com.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11272027.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill
2. Study examines benefit of follow-up CT when abdominal ultrasound inconclusive
3. 6 month follow-up of patients with benign MRI-guided breast biopsies may not be necessary
4. Medical follow-up in celiac disease is less than optimal
5. Missing Follow-Up Colonoscopies Could Raise Colon Cancer Risk
6. A Viagra follow-up? Drug used to treat glaucoma actually grows human hair
7. Less than half of youth with mental illness received adequate follow-up care, new study finds
8. 5-year follow-up - over half of all ACL reconstructions could be avoided
9. Evidence shows concussions require long-term follow-up for players
10. Follow-Up Care After Chest Pain Called Crucial
11. Chernobyl follow-up study finds high survival rate among young thyroid cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign that ... an app that lets users make and share payments through a smart device. In ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... In sleep, ... form as a dream. A hallmark feature of patients with eating disorders is significant ... The eating disorder behaviors and obsessions are regarded as maladaptive means for coping with ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. The ... known bugs within the app. Calls Blacklist allows its users to only have to ... their device’s battery power or memory. It provides a powerful call blocker that is ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
Breaking Medicine Technology: